Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NewAmsterdam Pharma Co N.V (NAMS) Net Margin: 2023-2025

Historic Net Margin for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Sep 2025 value amounting to -20,691.09%.

  • NewAmsterdam Pharma Co N.V's Net Margin fell 2063391.00% to -20,691.09% in Q3 2025 from the same period last year, while for Sep 2025 it was -627.28%, marking a year-over-year decrease of 3524.00%. This contributed to the annual value of -530.25% for FY2024, which is 72551.00% up from last year.
  • Latest data reveals that NewAmsterdam Pharma Co N.V reported Net Margin of -20,691.09% as of Q3 2025, which was down 22,713.35% from -90.70% recorded in Q2 2025.
  • NewAmsterdam Pharma Co N.V's 5-year Net Margin high stood at -57.18% for Q3 2024, and its period low was -20,691.09% during Q3 2025.
  • Moreover, its 3-year median value for Net Margin was -1,602.62% (2023), whereas its average is -3,797.50%.
  • As far as peak fluctuations go, NewAmsterdam Pharma Co N.V's Net Margin surged by 543,869bps in 2024, and later plummeted by 2,063,391bps in 2025.
  • Over the past 3 years, NewAmsterdam Pharma Co N.V's Net Margin (Quarterly) stood at -6,160.40% in 2023, then surged by 543,869bps to -721.71% in 2024, then plummeted by 2,063,391bps to -20,691.09% in 2025.
  • Its Net Margin was -20,691.09% in Q3 2025, compared to -90.70% in Q2 2025 and -1,327.30% in Q1 2025.